MK8722 initiates early-stage autophagy while inhibiting late-stage autophagy via FASN-dependent reprogramming of lipid metabolism
Luhui Wang, Haiyan Zhu, Zhehao Shi, Bo Chen, Huirong Huang, Ganglian Lin, Jiacheng Li, Haitao Yu, Shihao Xu, Gang Chen, Rongying Ou, Chunxiu Dai
Abstract
The findings suggest that using MK8722 may be a new strategy for treating EOC, as it has the potential to be a new autophagy/mitophagy inhibitor. Its target of action, FASN, is a molecular crosstalk between lipid metabolism and autophagy, and exploration of the underlying mechanism of FASN may provide a new research direction.
Topics & Concepts
AutophagyPI3K/AKT/mTOR pathwayAutophagosomeLipid metabolismCell biologyMitophagyGene silencingATG5ChemistryBECN1Lipid dropletKinaseCancer researchProtein kinase BBiologyApoptosisSignal transductionBiochemistryGeneAutophagy in Disease and TherapyMetabolism, Diabetes, and CancerCancer, Hypoxia, and Metabolism